About Biolife
Biolife, L.L.C. is a privately owned company, founded in 1999 by Jim Reding, Charlie
Entenmann, John “Alf” Thompson and James Patterson, Ph.D and is headquartered in
Sarasota, Florida. In 2005, Biolife was recognized as the Florida Entrepreneurial Company
of the Year.
Biolife’s Vision, Mission and Values
Biolife’s vision is to contribute to the universal greater good by providing products that
save lives and reduce pain and suffering.
Biolife’s mission is to develop and market products that improve our consumer’s
quality of life.
Biolife’s values guide us in fulfilling our mission. Each of us strives to:
• Maintain a cutomer focus - both internal and external
• Be process oriented - use analysis of data to continuously improve
• Maintain integrity in everything we do
• Respect one another
• Enjoy ourselves
The Technology
Biolife has patented a breakthrough topical powder that forms a seal over a bleeding wound
or an access site. The powder stops bleeding and allows "nothing in and nothing out" of a
wound.
The original technology was developed in a lab by Thompson and Patterson by accident. They
were testing the potassium iron oxyacid salt for other purposes when Patterson cut his hand
and the powder came into contact with the cut. He was on blood thinners and the cut was
fairly deep, so he figured a trip to the emergency room was inevitable. Patterson was shocked
when the powder mixed with the blood and formed an instant scab that stopped the bleeding.
All that was known at the time was that the powder stopped bleeding very quickly regardless
of one’s ability to clot naturally.
That discovery was just the beginning. Since then, Biolife, L.L.C. has taken the product from
conception to commercialization and continues to test the product to develop new and
improved applications. Biolife has produced and sold over 5 million applications of the
technology to leading hospitals, occupational workplaces, professional sports teams and
consumers across the country.
Advisory Boards
Biolife has advisory boards for each key business segment. These groups provide insights
and objective feedback that guide our product development and commercialization.
Regulatory Status
Biolife has FDA (510k) clearance to market our products in the U.S. The products have
passed all required safety, toxicity and biocompatibility testing. As new healthcare indications
emerge, we are preparing and submitting additional 510k filings as required. For more
information on our regulatory status, please contact us at customer.care@biolife.com
Patents
The patent for the technology was filed on February 9, 2000. The patent number is
6,187,347. Other US and International Patents Pending.
Biolife, L.L.C. is a privately owned company, founded in 1999 by Jim Reding, Charlie
Entenmann, John “Alf” Thompson and James Patterson, Ph.D and is headquartered in
Sarasota, Florida. In 2005, Biolife was recognized as the Florida Entrepreneurial Company
of the Year.
Biolife’s Vision, Mission and Values
Biolife’s vision is to contribute to the universal greater good by providing products that
save lives and reduce pain and suffering.
Biolife’s mission is to develop and market products that improve our consumer’s
quality of life.
Biolife’s values guide us in fulfilling our mission. Each of us strives to:
• Maintain a cutomer focus - both internal and external
• Be process oriented - use analysis of data to continuously improve
• Maintain integrity in everything we do
• Respect one another
• Enjoy ourselves
The Technology
Biolife has patented a breakthrough topical powder that forms a seal over a bleeding wound
or an access site. The powder stops bleeding and allows "nothing in and nothing out" of a
wound.
The original technology was developed in a lab by Thompson and Patterson by accident. They
were testing the potassium iron oxyacid salt for other purposes when Patterson cut his hand
and the powder came into contact with the cut. He was on blood thinners and the cut was
fairly deep, so he figured a trip to the emergency room was inevitable. Patterson was shocked
when the powder mixed with the blood and formed an instant scab that stopped the bleeding.
All that was known at the time was that the powder stopped bleeding very quickly regardless
of one’s ability to clot naturally.
That discovery was just the beginning. Since then, Biolife, L.L.C. has taken the product from
conception to commercialization and continues to test the product to develop new and
improved applications. Biolife has produced and sold over 5 million applications of the
technology to leading hospitals, occupational workplaces, professional sports teams and
consumers across the country.
Advisory Boards
Biolife has advisory boards for each key business segment. These groups provide insights
and objective feedback that guide our product development and commercialization.
Regulatory Status
Biolife has FDA (510k) clearance to market our products in the U.S. The products have
passed all required safety, toxicity and biocompatibility testing. As new healthcare indications
emerge, we are preparing and submitting additional 510k filings as required. For more
information on our regulatory status, please contact us at customer.care@biolife.com
Patents
The patent for the technology was filed on February 9, 2000. The patent number is
6,187,347. Other US and International Patents Pending.
 | |  | |  | |  | |  |
| Charlie Entenmann |
| The Late John "Alf" Thompson |
| The Late James Patterson "Doc" |
| Board of Directors Ed Bavaria – Chairman Charlie Entenmann Bob Reding Joanne Reding Sam Shake Bill Bold Tim Kelly |
| Management Team Sam Shake – President and CEO Tim Kelly - Executive Vice President Andrew McFall - Vice President of Marketing Kelly Keene - Director of R&D Michele Slingluff - Chief Financial Officer Roger Thomas - Strategic Support Projects |
| Empowering The World With A Revolutionary Powder |
| © 2011 Biolife LLC. All rights reserved. An ISO 13485:2003 Certified Company ► 941-360-1300 ► 800-722-7559 Toll Free ► Email US |